Hyperrab S/D

/ Perrigo

The recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose. It may also be given through the seventh day after the first dose of vaccine is given. If anatomically feasible, up to the full dose of HyperRAB S/D should be thoroughly infiltrated in the area around the wound and the rest should be administered intramuscularly in the deltoid muscle of the upper arm or lateral thigh muscle. The gluteal region should not be used as an injection site because of risk of injury to the sciatic nerve. HyperRAB S/D should never be administered in the same syringe or into the same anatomical site as vaccine.
Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.
See prescribing information for full details.

To be given in conjunction with rabies vaccine, as promptly as possible after exposure. Can be administered up to the eighth day after the first dose of vaccine.
See prescribing information for full details.

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

Repeated doses should not be administered once vaccine treatment has been initiated. Antibodies in the preparation may interfere with the response to live vaccines such as measles, mumps, polio or rubella and these should therefore not be given within three months after BayRab administration.

Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock have been rarely reported.

Live vaccines such as measles, mumps, polio or rubella.

Should be given during pregnancy only if clearly needed.